Multidisciplinary approach in management of patients with immune thrombocytopenia and ischemic heart disease

Cover Page

Cite item

Full Text

Abstract

Immune thrombocytopenia in patients with concomitant cardiovascular disorders requiring antiplatelet and anticoagulant therapy can increase the risk of hemorrhages and arterial and venous thromboembolic complications. This situation necessitates special patient management. Multidisciplinary approach is important for patients requiring myocardial revascularization due to the necessity of administration of double or triple antiplatelet therapy.
The article presents our experience in management of patients with immune thrombocytopenia and high functional class stable angina requiring coronary artery stent.

About the authors

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Author for correspondence.
Email: gemonk.yur@mail.ru
ORCID iD: 0000-0001-8443-8816

Yulia Evgenyevna Ryabukhina 

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081 

Russian Federation

A. A. Akhobekov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-6395-5790

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081 

Russian Federation

A. M. Grigoryan

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0001-9226-0130

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081 

Russian Federation

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies ; Department of Oncology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-1564-424X

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081 

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

M. M. Dombrovsky

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0003-1639-7332

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081 

Russian Federation

T. I. Kopaliani

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0009-0009-8543-6017

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081 

Russian Federation

T. T. Valiev

Department of Oncology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0002-1469-2365

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

References

  1. Matzdorff A., Meyer O., Ostermann H. et al. Immune Thrombocytopenia – current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat 2018;41(suppl 5):1–30 doi: 10.1159/000492187
  2. Idiopathic thrombocytopenic purpura (ITP) for adults. Clinical recommendations. 2021. (In Russ.). Available by: https://cr.minzdrav.gov.ru/schema/150_2
  3. Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–86. doi: 10.1182/blood-2009-06-225565
  4. Perera M., Garrido T. Advances in the pathophysiology of primary immune thrombocytopenia. Hematology 2017;22(1):41–53. doi: 10.1080/10245332.2016.1219497
  5. Audia S., Mahévas M., Samson M. et al. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 2017;16(6):620–32. doi: 10.1016/j.autrev.2017.04.012
  6. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012;2012:306–12. doi: 10.1182/asheducation-2012.1.306
  7. Cines D.B., Bussel J.B., Liebman H.A. et al. ITP syndrome: pathogenic and clinical diversity. Blood 2009;113(26):6511–21. doi: 10.1182/blood-2009-01-129155
  8. Sarpatwari A., Bennett D., Logie J.W. et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010;95(7):1167–75. doi: 10.3324/haematol.2009.018390
  9. Doobaree I.U., Nandigam R., Bennett D. et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol 2016;97(4):321–30. doi: 10.1111/ejh.12777
  10. Adelborg K., Kristensen N.R., Nørgaard M. et al. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. J Thromb Haemost 2019;17(6):912–24. doi: 10.1111/jth.14446
  11. Yakovlev A.N. Antiaggregants in cardiology: choice of best individual treatment. Meditsinskiy sovet = Medical Council 2015;(12):34-43. (In Russ.). doi: 10.21518/2079-701X-2015-12-34-43
  12. Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41(3):407–77. doi: 10.1093/eurheartj/ehz425
  13. Yusuf S., Zhao F., Mehta S.R. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494e502. doi: 10.1056/NEJMoa010746
  14. Vrints Ch., Andreotti F., Koskinas K.C. et al. ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45(36):3415–537. doi: 10.1093/eurheartj/ehae177
  15. McCarthy C.P., Steg G., Bhatt D.L. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J 2017;38(47):3488–92. doi: 10.1093/eurheartj/ehx531
  16. Lebowa W., Zdziarska J., Sacha T. Immune thrombocytopenia: characteristics of the population and treatment methods – one-center experience. Hamostaseologie 2023;43(2):132–41. doi: 10.1055/a-1767-0304
  17. Kuter D.J. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013;98(1):10–23. doi: 10.1007/s12185-013-1382-0
  18. Vinogradova O.Yu., Pankrashkina M.M., Neverova A.L. et al. Primary immune thrombocytopenia and thrombopoietin receptoragonists: feasibilities of treatment discontinuation upon achieving stable complete platelet response. Klinicheskaya onkogematologiya = Clinical Oncohematology 2023;16(4):413–25. (In Russ.). doi: 10.21320/2500–2139-2023-16-4-413-425
  19. Ploume E.H., Wolcherink M.J.O., Buiten R.A. et al. Cost-effectiveness of three different new-generation drug-eluting stents in the randomised BIO-RESORT trial at 3 years. Pharmacoecon Open 2025;9(1):137–45. doi: 10.1007/s41669-024-00539-x
  20. Navarese E.P., Kowalewski M., Kandzari D. et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014;1:e000064. doi: 10.1136/openhrt-2014-000064

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.